Experimental and clinical treatment of Chagas disease : a review.
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFOP |
Texto Completo: | http://www.repositorio.ufop.br/handle/123456789/10830 |
Resumo: | Chagas disease (CD) is caused by the protozoan parasite Trypanosoma cruzi that infects a broad range of triatomines and mammalian species, including man. It afflicts 8 million people in Latin America, and its incidence is increasing in nonendemic countries owing to rising international immigration and nonvectorial transmission routes such as blood donation. Since the 1960s, the only drugs available for the clinical treatment of this infection have been benznidazole (BZ) and nifurtimox (NFX). Treatment with these trypanocidal drugs is recommended in both the acute and chronic phases of CD. These drugs have low cure rates mainly during the chronic phase, in addition both drugs present side effects that may result in the interruption of the treatment. Thus, more efficient and better-tolerated new drugs or pharmaceutical formulations containing BZ or NFX are urgently needed. Here, we review the drugs currently used for CD chemotherapy, ongoing clinical assays, and most-promising new experimental drugs. In addition, the mechanism of action of the commercially available drugs, NFX and BZ, the biodistribution of the latter, and the potential for novel formulations of BZ based on nanotechnology are discussed. Taken together, the literature emphasizes the urgent need for new therapies for acute and chronic CD. |
id |
UFOP_6e2a07108cb9c6b76204cc2fdbd69b1f |
---|---|
oai_identifier_str |
oai:localhost:123456789/10830 |
network_acronym_str |
UFOP |
network_name_str |
Repositório Institucional da UFOP |
repository_id_str |
3233 |
spelling |
Sales Júnior, Policarpo AdemarMolina, IsraelMurta, Silvane Maria FonsecaSánchez Montalvá, AdriánSalvador, FernandoOliveira, Rodrigo Corrêa deCarneiro, Cláudia Martins2019-03-26T17:26:52Z2019-03-26T17:26:52Z2017SALES JÚNIOR, P. A. et al. Experimental and clinical treatment of Chagas disease : a review. The American Society of Tropical Medicine and Hygiene, v. 97, n. 5, p. 1289-1303, 2017. Disponível em: <http://www.ajtmh.org/docserver/fulltext/14761645/97/5/tpmd160761.pdf?expires=1551279084&id=id&accname=guest&checksum=3C4328E440B8C2D7A5A5F01F38C8FF26>. Acesso em: 21 fev. 2019.00029637http://www.repositorio.ufop.br/handle/123456789/10830Chagas disease (CD) is caused by the protozoan parasite Trypanosoma cruzi that infects a broad range of triatomines and mammalian species, including man. It afflicts 8 million people in Latin America, and its incidence is increasing in nonendemic countries owing to rising international immigration and nonvectorial transmission routes such as blood donation. Since the 1960s, the only drugs available for the clinical treatment of this infection have been benznidazole (BZ) and nifurtimox (NFX). Treatment with these trypanocidal drugs is recommended in both the acute and chronic phases of CD. These drugs have low cure rates mainly during the chronic phase, in addition both drugs present side effects that may result in the interruption of the treatment. Thus, more efficient and better-tolerated new drugs or pharmaceutical formulations containing BZ or NFX are urgently needed. Here, we review the drugs currently used for CD chemotherapy, ongoing clinical assays, and most-promising new experimental drugs. In addition, the mechanism of action of the commercially available drugs, NFX and BZ, the biodistribution of the latter, and the potential for novel formulations of BZ based on nanotechnology are discussed. Taken together, the literature emphasizes the urgent need for new therapies for acute and chronic CD.Authors of papers published by American Journal of Tropical Medicine and Hygiene have permission to reuse their own content without seeking further permission, provided that the original source of the material is credited appropriately. Fonte: American Journal of Tropical Medicine and Hygiene <https://www.ajtmh.org/reprints>. Acesso em: 25 fev. 2019.info:eu-repo/semantics/openAccessExperimental and clinical treatment of Chagas disease : a review.info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleengreponame:Repositório Institucional da UFOPinstname:Universidade Federal de Ouro Preto (UFOP)instacron:UFOPLICENSElicense.txtlicense.txttext/plain; charset=utf-8924http://www.repositorio.ufop.br/bitstream/123456789/10830/2/license.txt62604f8d955274beb56c80ce1ee5dcaeMD52ORIGINALARTIGO_ExperimentalClinicalTreatment.pdfARTIGO_ExperimentalClinicalTreatment.pdfapplication/pdf463792http://www.repositorio.ufop.br/bitstream/123456789/10830/1/ARTIGO_ExperimentalClinicalTreatment.pdf64d0675ce1758613337520df31a332deMD51123456789/108302019-03-26 13:26:52.377oai:localhost:123456789/10830RGVjbGFyYcOnw6NvIGRlIGRpc3RyaWJ1acOnw6NvIG7Do28tZXhjbHVzaXZhCgpPIHJlZmVyaWRvIGF1dG9yOgoKYSlEZWNsYXJhIHF1ZSBvIGRvY3VtZW50byBlbnRyZWd1ZSDDqSBzZXUgdHJhYmFsaG8gb3JpZ2luYWwgZSBxdWUgZGV0w6ltIG8gZGlyZWl0byBkZSBjb25jZWRlciBvcyBkaXJlaXRvcyBjb250aWRvcyBuZXN0YSBsaWNlbsOnYS4gRGVjbGFyYSB0YW1iw6ltIHF1ZSBhIGVudHJlZ2EgZG8gZG9jdW1lbnRvIG7Do28gaW5mcmluZ2UsIHRhbnRvIHF1YW50byBsaGUgw6kgcG9zc8OtdmVsIHNhYmVyLCBvcyBkaXJlaXRvcyBkZSBxdWFscXVlciBwZXNzb2Egb3UgZW50aWRhZGUuCgpiKVNlIG8gZG9jdW1lbnRvIGVudHJlZ3VlIGNvbnTDqW0gbWF0ZXJpYWwgZG8gcXVhbCBuw6NvIGRldMOpbSBvcyBkaXJlaXRvcyBkZSBhdXRvciwgZGVjbGFyYSBxdWUgb2J0ZXZlIGF1dG9yaXphw6fDo28gZG8gZGV0ZW50b3IgZG9zIGRpcmVpdG9zIGRlIGF1dG9yIHBhcmEgY29uY2VkZXIgw6AgVW5pdmVyc2lkYWRlIEZlZGVyYWwgZGUgT3VybyBQcmV0by9VRk9QIG9zIGRpcmVpdG9zIHJlcXVlcmlkb3MgcG9yIGVzdGEgbGljZW7Dp2EgZSBxdWUgZXNzZSBtYXRlcmlhbCwgY3Vqb3MgZGlyZWl0b3Mgc8OjbyBkZSB0ZXJjZWlyb3MsIGVzdMOhIGNsYXJhbWVudGUgaWRlbnRpZmljYWRvIGUgcmVjb25oZWNpZG8gbm8gdGV4dG8gb3UgY29udGXDumRvcyBkbyBkb2N1bWVudG8gZW50cmVndWUuCgpjKVNlIG8gZG9jdW1lbnRvIGVudHJlZ3VlIMOpIGJhc2VhZG8gZW0gdHJhYmFsaG8gZmluYW5jaWFkbyBvdSBhcG9pYWRvIHBvciBvdXRyYSBpbnN0aXR1acOnw6NvIHF1ZSBuw6NvIGEgVUZPUCwgZGVjbGFyYSBxdWUgY3VtcHJpdSBxdWFpc3F1ZXIgb2JyaWdhw6fDtWVzIGV4aWdpZGFzIHBlbG8gY29udHJhdG8gb3UgYWNvcmRvLgoKRepositório InstitucionalPUBhttp://www.repositorio.ufop.br/oai/requestrepositorio@ufop.edu.bropendoar:32332019-03-26T17:26:52Repositório Institucional da UFOP - Universidade Federal de Ouro Preto (UFOP)false |
dc.title.pt_BR.fl_str_mv |
Experimental and clinical treatment of Chagas disease : a review. |
title |
Experimental and clinical treatment of Chagas disease : a review. |
spellingShingle |
Experimental and clinical treatment of Chagas disease : a review. Sales Júnior, Policarpo Ademar |
title_short |
Experimental and clinical treatment of Chagas disease : a review. |
title_full |
Experimental and clinical treatment of Chagas disease : a review. |
title_fullStr |
Experimental and clinical treatment of Chagas disease : a review. |
title_full_unstemmed |
Experimental and clinical treatment of Chagas disease : a review. |
title_sort |
Experimental and clinical treatment of Chagas disease : a review. |
author |
Sales Júnior, Policarpo Ademar |
author_facet |
Sales Júnior, Policarpo Ademar Molina, Israel Murta, Silvane Maria Fonseca Sánchez Montalvá, Adrián Salvador, Fernando Oliveira, Rodrigo Corrêa de Carneiro, Cláudia Martins |
author_role |
author |
author2 |
Molina, Israel Murta, Silvane Maria Fonseca Sánchez Montalvá, Adrián Salvador, Fernando Oliveira, Rodrigo Corrêa de Carneiro, Cláudia Martins |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Sales Júnior, Policarpo Ademar Molina, Israel Murta, Silvane Maria Fonseca Sánchez Montalvá, Adrián Salvador, Fernando Oliveira, Rodrigo Corrêa de Carneiro, Cláudia Martins |
description |
Chagas disease (CD) is caused by the protozoan parasite Trypanosoma cruzi that infects a broad range of triatomines and mammalian species, including man. It afflicts 8 million people in Latin America, and its incidence is increasing in nonendemic countries owing to rising international immigration and nonvectorial transmission routes such as blood donation. Since the 1960s, the only drugs available for the clinical treatment of this infection have been benznidazole (BZ) and nifurtimox (NFX). Treatment with these trypanocidal drugs is recommended in both the acute and chronic phases of CD. These drugs have low cure rates mainly during the chronic phase, in addition both drugs present side effects that may result in the interruption of the treatment. Thus, more efficient and better-tolerated new drugs or pharmaceutical formulations containing BZ or NFX are urgently needed. Here, we review the drugs currently used for CD chemotherapy, ongoing clinical assays, and most-promising new experimental drugs. In addition, the mechanism of action of the commercially available drugs, NFX and BZ, the biodistribution of the latter, and the potential for novel formulations of BZ based on nanotechnology are discussed. Taken together, the literature emphasizes the urgent need for new therapies for acute and chronic CD. |
publishDate |
2017 |
dc.date.issued.fl_str_mv |
2017 |
dc.date.accessioned.fl_str_mv |
2019-03-26T17:26:52Z |
dc.date.available.fl_str_mv |
2019-03-26T17:26:52Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
SALES JÚNIOR, P. A. et al. Experimental and clinical treatment of Chagas disease : a review. The American Society of Tropical Medicine and Hygiene, v. 97, n. 5, p. 1289-1303, 2017. Disponível em: <http://www.ajtmh.org/docserver/fulltext/14761645/97/5/tpmd160761.pdf?expires=1551279084&id=id&accname=guest&checksum=3C4328E440B8C2D7A5A5F01F38C8FF26>. Acesso em: 21 fev. 2019. |
dc.identifier.uri.fl_str_mv |
http://www.repositorio.ufop.br/handle/123456789/10830 |
dc.identifier.issn.none.fl_str_mv |
00029637 |
identifier_str_mv |
SALES JÚNIOR, P. A. et al. Experimental and clinical treatment of Chagas disease : a review. The American Society of Tropical Medicine and Hygiene, v. 97, n. 5, p. 1289-1303, 2017. Disponível em: <http://www.ajtmh.org/docserver/fulltext/14761645/97/5/tpmd160761.pdf?expires=1551279084&id=id&accname=guest&checksum=3C4328E440B8C2D7A5A5F01F38C8FF26>. Acesso em: 21 fev. 2019. 00029637 |
url |
http://www.repositorio.ufop.br/handle/123456789/10830 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFOP instname:Universidade Federal de Ouro Preto (UFOP) instacron:UFOP |
instname_str |
Universidade Federal de Ouro Preto (UFOP) |
instacron_str |
UFOP |
institution |
UFOP |
reponame_str |
Repositório Institucional da UFOP |
collection |
Repositório Institucional da UFOP |
bitstream.url.fl_str_mv |
http://www.repositorio.ufop.br/bitstream/123456789/10830/2/license.txt http://www.repositorio.ufop.br/bitstream/123456789/10830/1/ARTIGO_ExperimentalClinicalTreatment.pdf |
bitstream.checksum.fl_str_mv |
62604f8d955274beb56c80ce1ee5dcae 64d0675ce1758613337520df31a332de |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFOP - Universidade Federal de Ouro Preto (UFOP) |
repository.mail.fl_str_mv |
repositorio@ufop.edu.br |
_version_ |
1801685745760468992 |